Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7262 alone and with enlicitide for elevated lipoprotein(a)
jRCT2021260024Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
01
Overview
Phase 2, randomised, double-blind trial of gefapixant and enlicitide in hyperlipoproteinemia and hyperlipidemia (4 arms), sponsored by Merck & Co. Primary endpoints: Percent change from baseline in lipoprotein(a) at Week 8, Percent change from baseline in LDL cholesterol at Week 8 and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
gefapixantenlicitide
03
Conditions
hyperlipoproteinemiahyperlipidemia
Beyond the preview
Go deeper on jRCT2021260024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260024.